Pitolisant

Ozawade (pitolisant) approved by EMA for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA) in adults

28th October 2021 The European Medicines Agency (EMA) has approved Bioprojet’s Ozawade (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA) in adults. Ozawade was evaluated in two Phase III clinical studies in the treatment of EDS in patients suffering from OSA – HAROSA…